Zoetis: Pets and Profits


Zoetis ( ZTS ) is the only publicly-traded pure-play in the animal health and vaccines market. This is a global growth business, making it an attractive long-term investment.

In terms of revenue, the company is the world leader in this market, and until this year, it was a wholly-owned division of Pfizer ( PFE ).

In January, Pfizer sold 20% of Zoetis to the public through an IPO. In June, Pfizer offered the remaining 80% to Pfizer shareholders through an exchange offer. The offer was substantially oversubscribed. Zoetis is now a fully independent company.

Zoetis offers animal health products for livestock and domestic pets. Sales of livestock-related products have grown at an 18.5% rate over the last three years. Pet-related products have grown at a 12.5% rate.

Zoetis is financially strong, with $468 million in cash and cash equivalents, and average net profit margins of 10%.

The debt/capital ratio is currently on the high side at 83% because Zoetis raised $3.65 billion through a bond issue just before the IPO.

Full-year earnings per share are expected to range from $1.36 to $1.42 on revenues of $4.425 billion to $4.525 billion. The current consensus among analysts is for full-year earnings of $1.40 on revenues of $5.522 billion.

Major research groups, including Argus, see Zoetis' earnings per share growing at an 11% compound rate over the next five years. Both Argus and Deutsche Bank research have a 12-month target price of $38 for Zoetis. They also agree on a 2014 earnings per share estimate of $1.62. There is a dividend of $0.26 per share per year for a current yield of less than 1%.

Following the conclusion of the Pfizer exchange offer, the stock dipped to a low of $28.97. My rating is to buy Zoetis below $30.

Editor's Note: This article was written by John Dessauer of John Dessauer's Outlook for MoneyShow .

Below, find some more great investing and trading content from MoneyShow :

Nutrisystem: Diet Dollars

Bristol-Myers: Blockbuster Pipeline?

Four Healthy Plays From the Chartist

Twitter: @TopProsTopPicks

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Stocks

Referenced Stocks: PFE , ZTS



More from Minyanville:

Related Videos

Top Home Financing Myths
Top Home Financing Myths            



Most Active by Volume

  • $17.88 ▼ 1.38%
  • $18.51 ▼ 6.98%
  • $94.01 ▼ 1.26%
  • $121.30 ▼ 0.87%
  • $23.28 ▼ 9.17%
  • $14.20 ▼ 0.77%
  • $14.83 ▼ 1.79%
  • $46.70 ▼ 0.38%
As of 7/31/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com